Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.46 |
| ▸ | RHEB | Q15382 | 3/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 5/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.34 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.34 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7208898 | 0.87 | PIM1 (0.45) | RIPK1RHEBBRD4PIM1EGLN1 | |
| SCHEMBL7208984 | 0.78 | RIPK1 (0.58) | RIPK1RHEBEGLN1KCNN1KCNN2 | |
| SCHEMBL8369973 | 0.73 | CYP1A2 (0.47) | — | |
| SCHEMBL7209326 | 0.73 | RHEB (0.44) | RHEBEGLN1 | |
| SCHEMBL7043130 | 0.70 | RHEB (0.54) | RHEBEGLN1 | |
| SCHEMBL11783950 | 0.70 | ADRA2A (0.46) | RHEB | |
| SCHEMBL8369927 | 0.69 | CYP1A2 (0.46) | RIPK1 | |
| SCHEMBL29000492 | 0.68 | GRIN2D (0.52) | RHEBEGLN1 | |
| SCHEMBL7044417 | 0.67 | RHEB (0.51) | RHEBEGLN1 | |
| SCHEMBL8873016 | 0.67 | RHEB (0.51) | RHEBEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6617315-B1 | Sugar-substituted benzimidazole derivatives are used for the treatment or prophylaxis of restenosis, particularly following angioplasty | CHAMBERLAIN STANLEY DAWES (US) | 2003-09-09 | — | — | US | disclosed |
| US-6204249-B1 | L-benzimidazole nucleosides | GLAXO WELLCOME INC. | 2001-03-20 | — | — | US | disclosed |